Last edition
News about "Bristol Myers Squibb"
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.
Bristol Myers Squibb | 30/03/2026 | By News Bureau
US FDA Clears Sotyktu for Active Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved Sotyktu, developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. The once-daily oral TYK2 inhibitor showed significantly higher ACR20 response rates versus placebo in the phase-III POETYK PsA-1 and PsA-2 trials.
Bristol Myers Squibb | 07/03/2026 | By News Bureau
Bristol Myers Squibb Reports Positive Phase II Data for Reblozyl in Alpha-Thalassemia
Bristol Myers Squibb’s Phase II trial shows Reblozyl significantly improved haemoglobin levels in non-transfusion-dependent patients and reduced transfusion burden in transfusion-dependent alpha-thalassemia, meeting all primary and key secondary endpoints.
Bristol Myers Squibb | 25/02/2026 | By News Bureau | 119
Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bristol Myers Squibb | 19/02/2026 | By News Bureau | 108
OXB Signs Multi-Year Commercial Supply Deal with Bristol Myers Squibb
Oxford Biomedica will serve as the commercial manufacturer of lentiviral vectors for Bristol Myers Squibb’s CAR-T programmes under a new multi-year supply agreement, which includes a five-year initial term with an option to extend.
Bristol Myers Squibb | 05/02/2026 | By News Bureau | 195
Janux Therapeutics has entered into a global collaboration and exclusive licensing agreement with Bristol Myers Squibb to develop a novel cancer therapy for solid tumours. The partnership is valued at up to USD eight hundred fifty million, including upfront payments and development, regulatory, and commercial milestones.
Bristol Myers Squibb | 23/01/2026 | By Darshana | 148
Syngene Renews Long-Term Research Alliance with Bristol Myers Squibb Until 2035
Syngene International has extended its long-term research collaboration with Bristol Myers Squibb until 2035, expanding the partnership to cover integrated services across the drug development lifecycle, from discovery and translational sciences to manufacturing, clinical trials and commercialisation support.
Bristol Myers Squibb | 20/01/2026 | By News Bureau
SCRI and Bristol Myers Squibb have expanded their collaboration to accelerate patient enrollment and extend access to advanced cancer clinical trials. By leveraging a data-driven strategy, the partnership aims to bring innovative research opportunities to a broader range of communities.
Bristol Myers Squibb | 15/11/2025 | By Dineshwori | 150
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec has reported advancement in its preclinical neuroscience collaboration with Bristol Myers Squibb, securing a payment of USD 25 Million to support the continued development of jointly pursued therapeutic programmes.
Bristol Myers Squibb | 28/10/2025 | By Dineshwori | 214
SystImmune and BMS Present Phase I Results of EGFR x HER3 Bispecific ADC at ESMO 2025
Iza-bren, a potentially first-in-class EGFR x HER3 bispecific Antibody-Drug Conjugate (ADC), is jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive licence agreement in territories outside of Mainland China.
Bristol Myers Squibb | 21/10/2025 | By Dineshwori | 308
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy